experienced breakthrough infection with SARS-CoV-2 variants; experienced breakthrough infection with SARS-CoV-2 variants; This literature-non-study case was reported in a literature article and describes the occurrence of VACCINE BREAKTHROUGH INFECTION (experienced breakthrough infection with SARS-CoV-2 variants) in an adult male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.   No Medical History information was reported.   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. In August 2021, the patient experienced COVID-19 (experienced breakthrough infection with SARS-CoV-2 variants) and VACCINE BREAKTHROUGH INFECTION (experienced breakthrough infection with SARS-CoV-2 variants) (seriousness criterion medically significant). At the time of the report, COVID-19 (experienced breakthrough infection with SARS-CoV-2 variants) and VACCINE BREAKTHROUGH INFECTION (experienced breakthrough infection with SARS-CoV-2 variants) outcome was unknown. Related    DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In August 2021, SARS-CoV-2 antibody test: positive (Positive) Positive (Delta variant).     For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered COVID-19 (experienced breakthrough infection with SARS-CoV-2 variants) and VACCINE BREAKTHROUGH INFECTION (experienced breakthrough infection with SARS-CoV-2 variants) to be related.    No concomitant and treatment medication were reported. Patient age range was  reported as 26-30 years Positive test to blood draw was 55 days Patient experienced breakthrough infection with delta variant  Company comment: This literature-non-study case concerns an adult male patient of unspecified age with no medical history reported, who experienced the unexpected non-serious AESI of COVID-19 (SARS-COV2 test positive) and unexpected serious event of Vaccine breakthrough infection (seriousness criteria medically significant) which occurred on unspecified day after second dose of mRNA-1273 vaccine. Patient experienced breakthrough infection with SARS-CoV-2 variants after second dose of vaccination. Neutralizing antibody titers was done. SARS-CoV-2 test was positive (Omicron variant) as on Aug 2021. No further details on clinical course, other lab test results and treatment received were reported. Outcome of the events was not known at the time of the report.  The benefit-risk relationship of mRNA-1273 is not affected by this report.   This case was linked to US-MODERNATX, INC.-MOD-2022-534254, US-MODERNATX, INC.-MOD-2022-534335, US-MODERNATX, INC.-MOD-2022-534338, US-MODERNATX, INC.-MOD-2022-534348, US-MODERNATX, INC.-MOD-2022-534363, US-MODERNATX, INC.-MOD-2022-534364, US-MODERNATX, INC.-MOD-2022-534365, US-MODERNATX, INC.-MOD-2022-534366, US-MODERNATX, INC.-MOD-2022-534367, US-MODERNATX, INC.-MOD-2022-534368, US-MODERNATX, INC.-MOD-2022-534369, US-MODERNATX, INC.-MOD-2022-534370, US-MODERNATX, INC.-MOD-2022-534371, US-MODERNATX, INC.-MOD-2022-534372, US-MODERNATX, INC.-MOD-2022-534373, US-MODERNATX, INC.-MOD-2022-534374, US-MODERNATX, INC.-MOD-2022-534391 (Linked Report).; Sender's Comments: This literature-non-study case concerns an adult male patient of unspecified age with no medical history reported, who experienced the unexpected non-serious AESI of COVID-19 (SARS-COV2 test positive) and unexpected serious event of Vaccine breakthrough infection (seriousness criteria medically significant) which occurred on unspecified day after second dose of mRNA-1273 vaccine. Patient experienced breakthrough infection with SARS-CoV-2 variants after second dose of vaccination. Neutralizing antibody titers was done. SARS-CoV-2 test was positive (Omicron variant) as on Aug 2021. No further details on clinical course, other lab test results and treatment received were reported. Outcome of the events was not known at the time of the report.  The benefit-risk relationship of mRNA-1273 is not affected by this report. US-MODERNATX, INC.-MOD-2022-534348:Same article, different patient US-MODERNATX, INC.-MOD-2022-534338:Same article, different patient US-MODERNATX, INC.-MOD-2022-534254:Same article, different patient US-MODERNATX, INC.-MOD-2022-534335:Same article, different patient US-MODERNATX, INC.-MOD-2022-534363:Same article, different patient US-MODERNATX, INC.-MOD-2022-534364:Same article, different patient US-MODERNATX, INC.-MOD-2022-534365:Same article, different patient US-MODERNATX, INC.-MOD-2022-534366:Same article, different patient US-MODERNATX, INC.-MOD-2022-534367:Same article, different patient US-MODERNATX, INC.-MOD-2022-534368:Same article, different patient US-MODERNATX, INC.-MOD-2022-534369:Same article, different patient US-MODERNATX, INC.-MOD-2022-534370:Same article, different patient US-MODERNATX, INC.-MOD-2022-534371:Same article, different patient US-MODERNATX, INC.-MOD-2022-534372:Same article, different patient US-MODERNATX, INC.-MOD-2022-534373:Same article, different patient US-MODERNATX, INC.-MOD-2022-534374:Same article, different patient US-MODERNATX, INC.-MOD-2022-534391:Same article, different patient